AxoGen (AXGN) Aandeel Koers
AxoGen Koers
De omzet is de afgelopen 19 jaar met 48,3% per jaar gegroeid tot 225,21 Miljoen USD. De nettowinstmarge van AxoGen ligt op -7,0% en is ten opzichte van -21,2% enkele jaren eerder gestegen. AxoGen biedt momenteel een dividendrendement van circa 2,65%. Analisten hanteren een mediaan koersdoel van 51,50 USD — dat impliceert 36,3% boven de huidige koers. Van de 16 analisten geven 15 het aandeel een koopadvies — per saldo een Kopen-consensus.
AxoGen aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
AxoGen bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over AxoGen
AxoGen Inc is a leading medical technology company focused on the development and commercialization of innovative solutions for peripheral nerve injuries. Their business model revolves around providing advanced surgical solutions to patients suffering from nerve damage. AxoGen offers a comprehensive portfolio of products and services that support nerve repair and regeneration, enabling patients to regain function and improve their quality of life. Through their cutting-edge technologies, AxoGen aims to revolutionize the field of peripheral nerve repair, bringing hope and relief to individuals with nerve injuries.
AxoGen Inc is primarily active in the healthcare industry.
The main competitors of AxoGen Inc in the market include Integra LifeSciences Holdings Corporation, Baxter International Inc., Stryker Corporation, and Medtronic plc.
AxoGen Inc. is a biotechnology company specializing in the development and commercialization of innovative surgical solutions for peripheral nerve injuries. Founded in 2002, AxoGen is headquartered in Alachua, Florida, and operates globally. The company is dedicated to advancing the science and understanding of nerve injury and regeneration through its proprietary Avance® Nerve Graft and AxoGuard® Nerve Protector products. With an experienced management team, AxoGen continues to drive innovation in nerve repair and restoration, providing hope and improved outcomes for patients suffering from nerve damage. AxoGen Inc. has established itself as a leader in the field, offering groundbreaking solutions to healthcare providers and patients worldwide.
AxoGen Inc has achieved several significant milestones throughout its history. The company has successfully developed and commercialized innovative nerve repair technology, making it a leader in the field. AxoGen has achieved FDA clearance and European CE mark approval for its products. It has also expanded its market presence by establishing distribution agreements with leading healthcare providers globally. AxoGen has consistently demonstrated strong financial performance, with increased revenues and record-breaking sales. The company's commitment to research and development has led to numerous patents and the introduction of groundbreaking surgical solutions. Overall, AxoGen Inc has made remarkable progress in transforming the field of nerve repair and continues to pave the way for future advancements.
AxoGen Inc is primarily present in the United States.
AxoGen Inc represents the values of innovation, collaboration, and patient-centricity. As a leading company in the field of nerve repair and regeneration, AxoGen is dedicated to developing and providing innovative solutions for patients with peripheral nerve injuries. Their corporate philosophy revolves around improving patient outcomes and enhancing the quality of life by delivering safe and effective treatments. By prioritizing collaboration with healthcare professionals and researchers, AxoGen ensures that their products are developed with the latest scientific advancements. With an unwavering commitment to patient well-being, AxoGen continues to make significant contributions to the field of nerve repair.
Analisten hanteren momenteel een gemiddeld koersdoel van 50,17 USD voor het aandeel AxoGen (mediaan: 51,50 USD), oftewel +36,8 % ten opzichte van de laatste koers. De consensus is gebaseerd op 16 analistenratings.
16 analisten beoordelen het aandeel AxoGen momenteel: 15 adviseren kopen, 1 houden en 0 verkopen. Voor 2026 verwachten analisten dat AxoGen een omzet van 283,33 Miljoen USD en winst per aandeel van 0,45 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel AxoGen op 33,68 EUR (37,78 USD).
Het aandeel AxoGen (AXGN) is genoteerd aan 4 beurzen, waaronder: NASDAQ (AXGN), London (0HKD.L), Frankfurt (LT3.F).
AxoGen Inc is a medical device company specializing in the development, manufacturing, and marketing of nerve repair products. The company, founded in 2002 in Florida, USA, aims to help improve patients' quality of life and alleviate pain and impairments caused by damages to peripheral nerves. They offer a range of products tailored to the specific needs of patients with nerve injuries, including the AxoGuard® Nerve Protector, biologics, regenerative medicine, neurostimulation, and the AxoTouch Test. The AxoGuard® Nerve Protector is designed to prevent damage to peripheral nerves and consists of breathable, implantable sleeves that provide protection. It is typically used to protect or repair nerves after surgery or due to injuries. Biologics, another branch of AxoGen Inc, involves the use of biological materials to accelerate the healing process of injured nerves, such as stem cells, Botulinum toxin injection, and antibodies to promote repair. Regenerative medicine products utilize regenerative forces to accelerate healing and promote the formation of new tissue, with Avance® Nerve Graft being the flagship product made from frozen human nerves processed mechanically and enzymatically to obtain a highly pure and biocompatible product. Neurostimulation focuses on the use of electronic devices to stimulate the nervous system, helping to alleviate pain and expedite healing. AxoStim® electrostimulation systems are among the products in this field. The AxoTouch Test is a diagnostic tool used to diagnose nerve damage, measuring pressure and touch sensitivity in the patient's body. It consists of a handheld instrument, a touch sensitivity measurement device, and specialized software packages for data analysis. AxoGen Inc's business model revolves around providing products for nerve damage regeneration, offering a comprehensive range of products tailored to patients' specific needs. The company is dedicated to developing innovative technologies and products to enhance the lives of individuals suffering from nerve damage and associated pain and impairments.
De verwachte omzet van AxoGen bedraagt 283,33 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van AxoGen bedraagt 20,90 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van AxoGen bedraagt momenteel 84,82. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het AxoGen-aandeel in te schatten.
De koers-omzetverhouding (P/S) van AxoGen bedraagt momenteel 6,26. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het AxoGen-aandeel.
De Eulerpool Kwaliteitsscore voor AxoGen is 4/10.
De ISIN van AxoGen is US05463X1063. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van AxoGen is A1JMHK. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van AxoGen is AXGN. Onder dit beurstickersymbool wordt het AxoGen-aandeel op de beurs verhandeld.
AxoGen aandeel
AxoGen Peer Group
AxoGen Ticker
AxoGen FIGI
Alle fundamentals en diepgaande analyse van AxoGen
Onze aandelenanalyse van het AxoGen-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van AxoGen. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: